In contrast, EGFR mutations in patients with carcinoembryonic antigen levels ≥ 2.12 ng/mL were associated with age (P = 0.002), nonsmokers (P = 0.038), tumour size (P = 0.010), histology (P < 0.001), and stage (P < 0.001, Table 2). This evidence concerns the gene EGFR and neoplasm.